diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5908diaendo-5908Research ArticleСтатьиArticlesСовременные возможности фармакотерапии сахарного диабета 2 типа при помощи аналогов глюкагоноподобного пептида-1 (ГПП-1)Sovremennye vozmozhnosti farmakoterapii sakharnogo diabeta 2 tipa pri pomoshchi analogov glyukagonopodobnogo peptida-1 (GPP-1)ШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna-ВикуловаОльга КонстантиновнаVikulovaOlga Konstantinovna-ФГУ Эндокринологический научный центр Росмедтехнологий, МоскваEndocrinology Research Centre, Moscow200715032007101№1 (2007)915Copyright © Шестакова М.В., Викулова О.К., 20072007Шестакова М.В., Викулова О.К.Shestakova M.V., Vikulova O.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5908

Миметик инкретинов ? экзенатид путем влияния на взаимодействие двух ключевых гормонов, регулирующих гомеостаз глюкозы, ? стимуляции глюкозозависимой секреции инсулина и подавления секреции глюкагона, восстанавливает естественные физиологические механизмы регуляции уровня гликемии. Экзенатид доказал свою высокую эффективность в многочисленных клинических исследованиях и может быть рекомендован для лечения больных СД 2 типа с неудовлетворительным контролем гликемии на пероральной са хароснижающей терапии, в том числе комбинированной.

сахарный диабет 2 типаГПП-1экзенатидReferencesLa Barre J. Sur les possibilities d'un traitement du diabete par l'incretine. Bull Acad R Med Belg 1932; 12:620-34.La Barre J. Sur les possibilities d'un traitement du diabete par l'incretine. Bull Acad R Med Belg 1932; 12:620-34.La Barre J. Studies on the physiology of secretin. Am J Physiol 1930; 91:649-53.La Barre J. Studies on the physiology of secretin. Am J Physiol 1930; 91:649-53.Elrick H, Stimmler L, Hlad CJ, Turner DA. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24:1076-82.Elrick H, Stimmler L, Hlad CJ, Turner DA. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24:1076-82.McIntryre N, Holdsworth CD, Turner DA. New interpretation of oral glucose tolerance. Lancet 1964; II: 20-1.McIntryre N, Holdsworth CD, Turner DA. New interpretation of oral glucose tolerance. Lancet 1964; II: 20-1.Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37:826-8.Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37:826-8.Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28:704-7.Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28:704-7.Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Rept 2003; 114:189-96/Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Rept 2003; 114:189-96/Holst JJ. GLP-1 receptor agonists for the treatment of diabetes. Int Diabetes Monitor 2005; 17(6):11-8.Holst JJ. GLP-1 receptor agonists for the treatment of diabetes. Int Diabetes Monitor 2005; 17(6):11-8.Eissele R, Goke R, Willemer S et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22:283-91.Eissele R, Goke R, Willemer S et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22:283-91.Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocinol 1996;10(4):342-55.Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocinol 1996;10(4):342-55.Dube PE, Brubaker PL. Nutrient, neural and endocrine control of glucagons-like peptide secretion. Horm Metab Res 2004; 36(11- 12):755-60.Dube PE, Brubaker PL. Nutrient, neural and endocrine control of glucagons-like peptide secretion. Horm Metab Res 2004; 36(11- 12):755-60.Mayo KE, Miller LJ, Bataille D et al. International Union of Pharmacology. XXXV. The glucagons receptor family. Pharmacol rev 2003; 55:167-94.Mayo KE, Miller LJ, Bataille D et al. International Union of Pharmacology. XXXV. The glucagons receptor family. Pharmacol rev 2003; 55:167-94.Holz GG. Epac: a new cAMP-binding protein in support of glucagonslike peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004; 53: 5-13.Holz GG. Epac: a new cAMP-binding protein in support of glucagonslike peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004; 53: 5-13.Gromada J, Dissing S, Bokvist K, Renstrom E, Frokjaer-Jensen J, Wulff BS, and Rorsman P. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes 1995; 44: 767-774.Gromada J, Dissing S, Bokvist K, Renstrom E, Frokjaer-Jensen J, Wulff BS, and Rorsman P. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes 1995; 44: 767-774.Fehmann HC and Habener JF. Insulinotropic hormone glucagon-like peptide- I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-166.Fehmann HC and Habener JF. Insulinotropic hormone glucagon-like peptide- I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-166.Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42:856-64.Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42:856-64.Perfetti R, Zhou J, Doyle ME, and Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose- intolerant rats. Endocrinology 2000; 141: 4600-4605.Perfetti R, Zhou J, Doyle ME, and Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose- intolerant rats. Endocrinology 2000; 141: 4600-4605.Zhou J, Wang X, Pineyro MA, and Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagons- and insulin-produsing cells. Diabetes 1990, 48: 2358-2366.Zhou J, Wang X, Pineyro MA, and Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagons- and insulin-produsing cells. Diabetes 1990, 48: 2358-2366.Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478.Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478.Shah P, Vella A, Rizza RA. Glucagon physiology, pathophysiology and prospects of glucagons antagonists for the treatment of diabetes. Int Diabetes Monitor 2005; 17(6): 3-10.Shah P, Vella A, Rizza RA. Glucagon physiology, pathophysiology and prospects of glucagons antagonists for the treatment of diabetes. Int Diabetes Monitor 2005; 17(6): 3-10.Moore MC, Cherrington AD. Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Reprod Nutr Dev 1996; 36: 399-406.Moore MC, Cherrington AD. Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Reprod Nutr Dev 1996; 36: 399-406.Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-4.Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-4.Zander M, Madsbad S, Madsen JL, and Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.Zander M, Madsbad S, Madsen JL, and Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8.Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8.Nauck MA, Bartels E, _rskov C et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide- 1-(7-36) amide infused at near- physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-7.Nauck MA, Bartels E, _rskov C et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide- 1-(7-36) amide infused at near- physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-7.Nauck MA, Heimesaat MM, _rskov C et al. Preserved incretin activity of glucagon-like peptide-1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.Nauck MA, Heimesaat MM, _rskov C et al. Preserved incretin activity of glucagon-like peptide-1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose- stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-6.Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose- stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-6.Vilsbol T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-9.Vilsbol T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-9.Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-7.Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-7.Nielsen LL, Young AA, Parkers DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Rept 2004; 117: 77-88.Nielsen LL, Young AA, Parkers DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Rept 2004; 117: 77-88.gan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87(3): 1282-90.gan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87(3): 1282-90.Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couterregulation during hypoglycemia. Diabetes 2004; 53(9): 2397-403.Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couterregulation during hypoglycemia. Diabetes 2004; 53(9): 2397-403.Fehse FC, Trautmann ME, Holst JJ, Halseth AE et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.Fehse FC, Trautmann ME, Holst JJ, Halseth AE et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.Kolterman OG, Buse JB, Fineman MS, Gaines E et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.Kolterman OG, Buse JB, Fineman MS, Gaines E et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.Kolterman O, Kim DD, Shen L, Ruggles JA et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.Kolterman O, Kim DD, Shen L, Ruggles JA et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.Edwards CMB, Stanley SA, Davis R et al. Exendin-4 reduses fasting and postprandial glucose decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281(1): E155-61.2.Edwards CMB, Stanley SA, Davis R et al. Exendin-4 reduses fasting and postprandial glucose decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281(1): E155-61.2.Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26(8): 2370-7.Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26(8): 2370-7.Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7(3): 467-77.Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7(3): 467-77.DeFronzo R, Ratner R, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-100.DeFronzo R, Ratner R, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-100.Buse J, Henry R, Han J et al. Effests of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2628-35.Buse J, Henry R, Han J et al. Effests of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2628-35.Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5):1083-91.Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5):1083-91.Ratner RE, Maggs D, Nielsen LL, Stonehouse AH et al. Long term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weigt metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; In Press.Ratner RE, Maggs D, Nielsen LL, Stonehouse AH et al. Long term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weigt metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; In Press.Kim D, Trautmann ME, Limmer J et al. Exenatide reduzierte HbA1c und gewicht uber 82 wochen bei patienten mit typ-2 diabetes [abstract no. V-20]. Diabetes Stoffwechsel 2005; 14(1): 10.Kim D, Trautmann ME, Limmer J et al. Exenatide reduzierte HbA1c und gewicht uber 82 wochen bei patienten mit typ-2 diabetes [abstract no. V-20]. Diabetes Stoffwechsel 2005; 14(1): 10.Kim D, Trautmann ME, Schonamsqruber E et al. Exenatide reduzierte HbA1c und gewicht uber 82 wochen bei mit metformin und sulfonylharnstoff behandelten patienten mit typ-2 diabetes [abstract no.P-349]. Diabetes Stoffwechsel 2005; 14(1): 161.Kim D, Trautmann ME, Schonamsqruber E et al. Exenatide reduzierte HbA1c und gewicht uber 82 wochen bei mit metformin und sulfonylharnstoff behandelten patienten mit typ-2 diabetes [abstract no.P-349]. Diabetes Stoffwechsel 2005; 14(1): 161.Kendall DM, Kim D, Poon T et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 wk [abstract no.16-OR]. Diabetes 2005; 54(1):A4-5.Kendall DM, Kim D, Poon T et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 wk [abstract no.16-OR]. Diabetes 2005; 54(1):A4-5.Heine RJ, Van Gaal LF, Johns D, Mihm M, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005; 143(8):559-569.Heine RJ, Van Gaal LF, Johns D, Mihm M, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005; 143(8):559-569.Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20:411-417.Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20:411-417.Maggs D, Kim D, Holcombe J, et al. Exenatide induced reduction in A1C and body weight in long-term trials are not explained by gastrointestinal side effects [abstract no.485-P]. Diabetes 2005; 54(1): A120.Maggs D, Kim D, Holcombe J, et al. Exenatide induced reduction in A1C and body weight in long-term trials are not explained by gastrointestinal side effects [abstract no.485-P]. Diabetes 2005; 54(1): A120.

The authors declare that there are no conflicts of interest present.